


Journal Pre-proof

Neuro-Ophthalmologic Complications of Coronavirus Disease 2019 (COVID-19)

Doria M. Gold, Steven L. Galetta



PII: S0304-3940(20)30801-6

DOI: <https://doi.org/10.1016/j.neulet.2020.135531>

Reference: NSL 135531

To appear in: *Neuroscience Letters*

Received Date: 11 October 2020

Accepted Date: 18 November 2020

Please cite this article as: Gold DM, Galetta SL, Neuro-Ophthalmologic Complications of Coronavirus Disease 2019 (COVID-19), *Neuroscience Letters* (2020), doi: <https://doi.org/10.1016/j.neulet.2020.135531>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.

Neuro-Ophthalmologic Complications of Coronavirus Disease 2019 (COVID-19)

Authors: Doria M. Gold, MD^a, Steven L. Galetta, MD^b

Doria M. Gold, MD (corresponding author)

^aNYU Langone Medical Center

Department of Neurology

222 E. 41st St.

New York, NY 10017

USA

Doria.gold@nyulangone.org

Steven L. Galetta, MD

^bNYU Langone Medical Center

Departments of Neurology and Ophthalmology

222 E. 41st St.

New York, NY 10017

USA

Steven.galetta@nyulangone.org

Highlights (not a full research article)

- Multiple neuro-ophthalmological manifestations have been described in association with COVID-19.
- These include optic neuritis, cranial nerve palsies, eye movement abnormalities and visual field defects.
- The mechanisms of involvement tend to fall within three general categories – a post-viral inflammatory syndrome, sequelae of a proinflammatory state, and the result of systemic abnormalities including hypoxia and severe hypertension.

Title: Neuro-Ophthalmologic Complications of Coronavirus Disease 2019 (COVID-19)**Abstract**

Multiple neuro-ophthalmological manifestations have been described in association with COVID-19. These symptoms and signs may be the result of a range of pathophysiological mechanisms throughout the course from acute illness to recovery phase. Optic nerve dysfunction, eye movement abnormalities and visual field defects have been described.

Keywords: COVID-19 infection; Neuro-ophthalmology; optic neuritis, cranial nerve palsy; Miller-Fisher variant Guillain Barre Syndrome; myasthenia gravis; opsoclonus; diplopia; oscillopsia; visual field defect; Stroke; venous sinus thrombosis

Introduction

In December 2019 reports of severe acute respiratory syndrome (SARS-CoV-2) due to coronavirus disease 2019 (COVID-19) causing pneumonia emerged out of Wuhan city in China.[1] The enveloped RNA betacoronavirus is hypothesized to employ the ACE2 binding receptor for infectivity.[1, 2] At the time of this article, it was confirmed to have infected nearly 34.5 million people worldwide and caused over 1 million deaths, causing an immense impact on society at large.[3]

While the most common symptoms include fever, cough, fatigue, and shortness of breath,[1, 4] COVID-19 is not purely a respiratory disease; indeed, the virus may produce a vast array of manifestations related to acute cardiac disease, acute kidney injury, vasculopathy, coagulopathy, elevated inflammatory markers, and neurological injury.[5] Presentations vary from completely asymptomatic carriers to severe illness with multiorgan failure and death.[5] Severe cases are

typically characterized by a heightened inflammatory and coagulopathic response that is thought to play a prominent role in the pathogenesis and mortality that is associated with this virus.[6]

Neuro-ophthalmic Manifestations

Multiple neuro-ophthalmological manifestations have been described in association with COVID-19. These symptoms and signs may be the result of varying underlying pathophysiological mechanisms including hypoxia, severe hypertension, toxic metabolic processes, ischemic and hemorrhagic strokes along with para-infectious and post-infectious inflammatory processes.

Optic Neuritis: Cases of optic neuritis have been described in patients who had proven COVID-19 infection. In a study examining the neurological complications of COVID-19 admitted to a single hospital in Spain, one case of optic neuritis was observed in the recovery phase.[4] Additionally there have been case reports of MOG antibody positivity in patients with either presumed[7] or confirmed[8] COVID-19 infection. One had bilateral optic nerve abnormalities including peripheral retinal hemorrhages that responded well to intravenous corticosteroids.[8] Presumably the COVID-19 infection triggered an autoimmune response and the production of MOG antibodies. It is unclear whether the patient harbored a predisposition to MOG associated disease or if the virus set the process in motion. An additional case of optic neuritis that was associated with other neurological deficits and consistent with acute disseminated encephalomyelitis (ADEM) has also been documented.[9]

Cranial Nerve Palsies: Both diplopia and ptosis have been described in patients shortly after diagnosis with typical COVID-19 infection. Several patients with ocular motor deficits within days of resolution of typical COVID-19 symptoms have been reported. These ocular motility deficits have been associated with paresthesias and hyporeflexia, suggesting the Miller-Fisher variant of the Guillain Barre syndrome.[10-14] In keeping with this diagnosis, cranial nerve inflammation on MRI has been observed.[10]

In another case series, three patients presented with several days of fever and active COVID-19 infection. They did not have sensory complaints, but rather noted generalized fatigability. These patients were assessed with EMG, which showed decremental response on repetitive nerve stimulation and positive acetylcholine receptor antibodies, consistent with a diagnosis of Myasthenia Gravis. Again, the COVID-19 infection may have exposed an unrecognized predisposition to this autoimmune process. The patients in this series recovered with various immunosuppressive agents to treat Myasthenia Gravis.[15] An additional report of an isolated abducens nerve palsy without identifiable lesion on an imaging study and of unclear etiology was described during the height of the pandemic.[16]

The hypercoagulable and proinflammatory state triggered by COVID-19 infection has been associated with cerebral venous sinus thromboses that may manifest with confusion and raised intracranial pressure. Increased intracranial pressure may produce a false localizing sixth nerve palsy as well as papilledema.[17-19] Pseudotumor cerebri syndrome has also been reported as a complication of multisystem inflammatory syndrome in children associated with

COVID-19 infection.[20] Chemosis has also been described in patients with severe infection and significant ocular exudate.[21]

Eye Movement Abnormalities and Nystagmus: Oscillopsia has been described in several case reports in association with ataxia and myoclonus, usually in the context of encephalopathy and following severe systemic involvement due to COVID-19 infection. These patients were found to have corresponding cerebellar lesions on MRI and bland cerebrospinal fluid[22, 23] consistent with a post-infectious immune-mediated rhomboencephalitis. In one case, the MRI did not show any structural lesion, however the time course of presentation, symptoms and bland CSF were felt to be consistent with this process.[24] A single case of opsoclonus myoclonus ataxia syndrome has been reported in a patient five days after resolution of fevers and myalgias typical of COVID-19 symptoms. There were no findings seen on brain MRI, but CT chest showed findings consistent with COVID-19 infection. The patient responded well to treatment with intravenous immunoglobulin and methylprednisolone treating an inflammatory cerebellar syndrome.[25] The authors (SLG personal communication) have also observed a patient with atypical ocular bobbing (slow phase up and fast phase down) in a patient who had transient white matter abnormalities in the bilateral superior cerebellar peduncles.

Visual Field Defects:

Stroke, especially in the younger population, has been one of the most notable and devastating neurological complications of COVID-19. With involvement of the posterior circulation and occipital lobes, visual field defects have been documented in these patients.[26-30] The entity of posterior reversible vasoconstriction syndrome (PRES) has been another

mechanism of injury in COVID-19 and some patients may experience transient visual field defects and MRI abnormalities.[31] There has been one report of hallucinatory palinopsia described in a patient with PRES due to COVID-19 infection with involvement of parieto-occipital lobes on MRI.[32]

Conclusion

The neuro-ophthalmological symptoms and signs associated with COVID-19 infection are varied and span the course of infection through the recovery phase. The mechanisms of involvement are still in the process of being completely elucidated, however, they tend to fall within three general categories – a post-viral inflammatory syndrome, sequelae of a proinflammatory state with hypercoagulability and “cytokine storm,” and the result of systemic abnormalities including hypoxia and severe hypertension. Direct viral invasion seems to be a rare manifestation of COVID-19 and we are unaware of neuro-ophthalmological findings that have been definitively produced by this potential mechanism.

References

- [1] W. J. Guan *et al.*, "Clinical Characteristics of Coronavirus Disease 2019 in China," *N Engl J Med*, vol. 382, no. 18, pp. 1708-1720, Apr 30 2020, doi: 10.1056/NEJMoa2002032.
- [2] R. Lu *et al.*, "Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding," *Lancet*, vol. 395, no. 10224, pp. 565-574, Feb 22 2020, doi: 10.1016/S0140-6736(20)30251-8.
- [3] WHO. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (accessed).
- [4] C. M. Romero-Sánchez *et al.*, "Neurologic manifestations in hospitalized patients with COVID-19," *Neurology*, vol. 95, no. 8, p. e1060, 2020, doi: 10.1212/WNL.00000000000009937.
- [5] B. High, A. M. Hixon, K. L. Tyler, A. L. Piquet, and V. S. Pelak, "Neurology and the COVID-19 Pandemic: Gathering Data for an Informed Response," *Neurology: Clinical Practice*, p. 10.1212/CPJ.0000000000000908, 2020, doi: 10.1212/CPJ.0000000000000908.
- [6] J. Xie, Z. Tong, X. Guan, B. Du, and H. Qiu, "Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China," *JAMA Netw Open*, vol. 3, no. 4, p. e205619, Apr 1 2020, doi: 10.1001/jamanetworkopen.2020.5619.
- [7] N. S. de Ruijter, G. Kramer, R. A. R. Gons, and G. J. D. Hengstman, "Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report," *Multiple Sclerosis and Related Disorders*, vol. 46, p. 102474, 2020/11/01/ 2020, doi: <https://doi.org/10.1016/j.msard.2020.102474>.
- [8] S. Zhou, E. C. Jones-Lopez, D. J. Soneji, C. J. Azevedo, and V. R. Patel, "Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis and Myelitis in COVID-19," *J Neuroophthalmol*, vol. 40, no. 3, pp. 398-402, Sep 2020, doi: 10.1097/WNO.0000000000001049.
- [9] G. Novi *et al.*, "Acute disseminated encephalomyelitis after SARS-CoV-2 infection," (in eng), *Neurol Neuroimmunol Neuroinflamm*, vol. 7, no. 5, p. e797, 2020, doi: 10.1212/NXI.0000000000000797.
- [10] M. Dinkin *et al.*, "COVID-19 presenting with ophthalmoparesis from cranial nerve palsy," *Neurology*, vol. 95, no. 5, pp. 221-223, Aug 4 2020, doi: 10.1212/WNL.00000000000009700.
- [11] C. Gutiérrez-Ortiz *et al.*, "Miller Fisher syndrome and polyneuritis cranialis in COVID-19," (in eng), *Neurology*, vol. 95, no. 5, pp. e601-e605, Aug 4 2020, doi: 10.1212/wnl.00000000000009619.
- [12] B. L. Assini A, Silvia DM, Erika S, Sette MD. , "New clinical manifestations of COVID-19 related Guillain Barre syndrome highly responsive to intravenous immunoglobulins: two Italian cases.," *Research Square*, 2020, doi: 10.21203/rs.3.rs-30354/v1.
- [13] J. A. Reyes-Bueno *et al.*, "Miller-Fisher syndrome after SARS-CoV-2 infection," *European Journal of Neurology*, vol. 27, no. 9, pp. 1759-1761, 2020/09/01 2020, doi: 10.1111/ene.14383.

- [14] P. Pinna *et al.*, "Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline," *Journal of the Neurological Sciences*, vol. 415, p. 116969, 2020/08/15/ 2020, doi: <https://doi.org/10.1016/j.jns.2020.116969>.
- [15] D. A. Restivo, D. Centonze, A. Alesina, and R. Marchese-Ragona, "Myasthenia Gravis Associated With SARS-CoV-2 Infection," *Annals of Internal Medicine*, 2020, doi: 10.7326/L20-0845.
- [16] C. Greer, J. Bhatt, C. Oliveira, and M. Dinkin, "Isolated cranial nerve six palsy in two patients with COVID-19 infection," *J Neuroophthalmol*, Sep 14 2020, doi: 10.1097/WNO.0000000000001146.
- [17] B. Shakibajahromi, A. Borhani-Haghighi, S. Haseli, and A. Mowla, "Cerebral venous sinus thrombosis might be under-diagnosed in the COVID-19 era," (in eng), *eNeurologicalSci*, vol. 20, pp. 100256-100256, 2020, doi: 10.1016/j.ensci.2020.100256.
- [18] D. D. Cavalcanti *et al.*, "Cerebral Venous Thrombosis Associated with COVID-19," (in eng), *AJNR Am J Neuroradiol*, vol. 41, no. 8, pp. 1370-1376, Aug 2020, doi: 10.3174/ajnr.A6644.
- [19] N. Eliseeva, N. Serova, S. Yakovlev, K. Mikeladze, Y. Arkhangelskaya, and S. Gasparyan, "Neuro-ophthalmological Features of Cerebral Venous Sinus Thrombosis," (in eng), *Neuroophthalmology*, vol. 39, no. 2, pp. 69-76, 2014, doi: 10.3109/01658107.2014.953697.
- [20] L. D. Verkuil, G. T. Liu, V. L. Brahma, and R. A. Avery, "Pseudotumor cerebri syndrome associated with MIS-C: a case report," *The Lancet*, vol. 396, no. 10250, p. 532, 2020/08/22/ 2020, doi: [https://doi.org/10.1016/S0140-6736\(20\)31725-6](https://doi.org/10.1016/S0140-6736(20)31725-6).
- [21] P. Wu *et al.*, "Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China," *JAMA Ophthalmol*, vol. 138, no. 5, pp. 575-578, May 1 2020, doi: 10.1001/jamaophthalmol.2020.1291.
- [22] L. Llorente Ayuso, P. Torres Rubio, R. F. Beijinho do Rosário, M. L. Giganto Arroyo, and F. Sierra-Hidalgo, "Bickerstaff encephalitis after COVID-19," *Journal of Neurology*, 2020/09/03 2020, doi: 10.1007/s00415-020-10201-1.
- [23] P. F. Wong *et al.*, "Lessons of the month 1: A case of rhombencephalitis as a rare complication of acute COVID-19 infection," *Clinical Medicine*, vol. 20, no. 3, p. 293, 2020, doi: 10.7861/clinmed.2020-0182.
- [24] A. Khoo *et al.*, "Postinfectious brainstem encephalitis associated with SARS-CoV-2," *Journal of Neurology, Neurosurgery & Psychiatry*, vol. 91, no. 9, p. 1013, 2020, doi: 10.1136/jnnp-2020-323816.
- [25] S. Sanguinetti and R. A. Ramdhani, "Opsoclonus Myoclonus Ataxia Syndrome Related to the Novel Coronavirus (COVID-19)," *J Neuroophthalmol*, Sep 7 2020, doi: 10.1097/WNO.0000000000001129.
- [26] S. Yaghi *et al.*, "SARS-CoV-2 and Stroke in a New York Healthcare System," *Stroke*, vol. 51, no. 7, pp. 2002-2011, 2020/07/01 2020, doi: 10.1161/STROKEAHA.120.030335.
- [27] J. T. Fifi and J. Mocco, "COVID-19 related stroke in young individuals," *The Lancet Neurology*, vol. 19, no. 9, pp. 713-715, 2020/09/01/ 2020, doi: [https://doi.org/10.1016/S1474-4422\(20\)30272-6](https://doi.org/10.1016/S1474-4422(20)30272-6).

- [28] L. Mao *et al.*, "Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China," *JAMA Neurology*, vol. 77, no. 6, pp. 683-690, 2020, doi: 10.1001/jamaneurol.2020.1127.
- [29] M. A. Ellul *et al.*, "Neurological associations of COVID-19," *Lancet Neurol*, vol. 19, no. 9, pp. 767-783, Sep 2020, doi: 10.1016/S1474-4422(20)30221-0.
- [30] R. Beyrouti *et al.*, "Characteristics of ischaemic stroke associated with COVID-19," *J Neurol Neurosurg Psychiatry*, vol. 91, no. 8, pp. 889-891, Aug 2020, doi: 10.1136/jnnp-2020-323586.
- [31] S. C. Parauda *et al.*, "Posterior reversible encephalopathy syndrome in patients with COVID-19," *Journal of the Neurological Sciences*, vol. 416, p. 117019, 2020/09/15/ 2020, doi: <https://doi.org/10.1016/j.jns.2020.117019>.
- [32] R. Ghosh, D. Lahiri, S. Dubey, B. K. Ray, and J. Benito-Leon, "Hallucinatory palinopsia in COVID-19 induced posterior reversible encephalopathy syndrome," *J Neuroophthalmol*, Sep 7 2020, doi: 10.1097/WNO.0000000000001135.